secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-05-27T12:00:25+00:00
Accession:  0001493152-26-025335
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA secures worldwide rights for Ketamir-2, expands IP to 10 markets ahead of Phase 2a
--------------------------------------------------------------------------------

- Amendment expands licensed territory from US, Canada, Mexico to all countries with patent rights.
- IP portfolio now covers filings in 10 markets: US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, S. Korea.
- Core economic terms (royalties, financial consideration) of original license agreement unchanged.
- Company advancing Phase 2a protocol for FDA submission after positive Phase 1 data in 56 volunteers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226025335/0001493152-26-025335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226025335/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer